- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 834359, 6 pages
Stanniocalcin-1 Co-Localizes with Insulin in the Pancreatic Islets
Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada N6A 5C1
Received 2 August 2012; Accepted 9 September 2012
Academic Editors: A. De Bellis and D. G. Romero
Copyright © 2012 Deenaz Zaidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The polypeptide hormone stanniocalcin-1 (STC-1) is widely expressed in mammals and signals both locally and systemically. In many tissues STC-1 ligand is sequestered by target cell organelles (mitochondria, nuclei, and cholesterol lipid droplets) to exert diverse biological effects. Most notably, STC-1 serves as an uncoupler of oxidative phosphorylation in liver, muscle, and kidney mitochondria. The present paper describes the identification of STC-1 receptors in mouse pancreatic β cells and the discovery that the ligand co-localizes with insulin in pancreatic β cells. In situ hybridization (ISH) analysis subsequently revealed that pancreatic β cells were the source of the ligand. Intriguingly however, all ISH signal was localized over putative islet cell nuclei as opposed to the cell cytoplasm. Real-time qPCR and agarose gel electrophoresis revealed that the STC-1 amplicon generated from islet cell total RNA was the same size as that from kidney. However, relative levels of STC-1 gene expression were >100-fold lower in islets than those in kidney tissue. Collectively, these findings are indicative of a local STC-1 signalling pathway in pancreatic β cells. The role of STC-1 in this context remains to be established, but it could very well entail the regulation of β cell mitochondria membrane potential which is an integral aspect of regulated insulin release. Interestingly, STC-1 immunoreactivity was not evident in embryonic pancreatic islets, suggesting that ligand synthesis may only commence postnatally.
The polypeptide hormone stanniocalcin-1 (STC-1) was originally identified as an endocrine regulator of serum calcium levels in fish . However, the mammalian homologue appears to have more metabolically related functions. In kidney, liver, and muscle cells, STC-1 is targeted to and sequestered by the mitochondria where it uncouples oxidative phosphorylation. The resulting proton gradient energy is used instead to drive mitochondrial calcium transport and is possibly part of the mechanism by which STC-1 exerts antiapoptotic effects . In luteal cells, STC-1 is targeted to and sequestered by the cholesterol lipid droplets to negatively regulate progesterone synthesis . A nuclear targeting pathway becomes operative during pregnancy and lactation, whereby STC-1 is delivered systemically to mammary gland alveolar cells to promote milk fat synthesis . In all the examples described above, the organelles in question possess saturable, high affinity STC-1 receptors that aid in ligand uptake and sequestration .
In the course of mapping the distribution of STC-1 receptors in mammalian tissues, we have examined the pancreas because of its well established role in intermediary metabolism. This paper describes the colocalization of STC-1 mRNA, ligand, and receptor to insulin-producing, mouse pancreatic β cells.
2. Materials and Methods
2.1. Histological Techniques
CD-1 male and pregnant female mice (Charles River Laboratories, Montreal, QC, Canada) were obtained for histological analysis of pancreatic tissue. Mice were anaesthetized via an i.p. injection of Somnitol (63 mg/kg) and subjected to intracardiac perfusion with phosphate buffered saline, pH 7.4, (PBS) containing 4% paraformaldehyde. Pancreatic tissue was then removed, postfixed overnight in PFA, and embedded in paraffin. Late stage mouse embryos (e17.5) were fixed and embedded in paraffin as previously described . All tissue sections were cut at a thickness of 6 microns and routinely stained with haematoxylin and eosin.
2.1.1. Immunocytochemistry (ICC)
ICC was performed as previously described [5, 6] using polyclonal antisera to recombinant hSTC-1 and a mouse monoclonal antibody to rat insulin (Sigma Chemicals, St. Louis, Mo, USA). Tissue sections were incubated overnight at 4°C with 1 : 200 and 1 : 1000 dilutions of insulin and STC-1 antisera, respectively. In the case of mouse embryos, sites of antibody binding were visualized with biotinylated secondary antibodies and the Vectastain ABC peroxidase detection system (Vector Laboratories, Burlingame, CA, USA). In adult mouse pancreas, sites of antibody binding were visualized with FITC-conjugated goat anti-rabbit gamma globulin for STC-1 and Texas red-conjugated goat anti-mouse gamma globulin in the case of insulin (Vector Laboratories, Burlingame, CA, USA). As staining controls, tissue sections were incubated in normal rabbit serum (NRS) in lieu of antiserum or antiserum preabsorbed with excess antigen. Slides were washed in PBS and mounted for confocal imaging (Bio-Rad Radiance 2000 laser scanning system).
2.1.2. In Situ Ligand Binding (ISLB)
ISLB was performed on both adult and e17.5 embryonic mouse pancreas as previously described for the cellular localization of STC receptors [4, 7]. The method employs a fusion protein of stanniocalcin (STC) and human placental alkaline phosphatase (AP), referred to as STC-AP. Briefly, tissue sections were equilibrated in Hanks balanced salt solution containing 0.1% BSA pH 7.5 and then incubated for 90 min in the same buffer containing 1 nM STC-AP. Control slides were incubated in either AP alone or STC-AP containing 1 μM hSTC. Slides were then washed, processed for visualization of bound AP activity as described in [4, 7], dehydrated, and mounted.
2.1.3. In Situ Hybridization (ISH)
For ISH on adult mouse pancreas, a 900 bp cDNA encoding the entire open reading frame of mouse STC-1  was used as a template for digoxigenin-labelled riboprobe synthesis in sense and antisense orientations (Amersham Pharmacia Biotech, Canada). The ISH procedure was then conducted as previously described [5, 6, 8]. Three animals were analyzed and images were captured via brightfield microscopy using a digital camera.
2.2. Tissue RNA Isolation and Quantitative PCR
Samples of fresh rat kidney, rat liver, and isolated rat pancreatic islets were homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA) with a motorized pestle and total RNA was isolated according to the manufacturer’s recommendations (Invitrogen, Carlsbad, CA, USA). Pancreatic islets were isolated by the collagenase method as previously described . Relative STC-1 mRNA levels were determined using TaqMan STC-1 gene expression assay and TaqMan one-step RT-PCR master mix (Applied Biosystems, Foster City, CA, USA) as previously described [10, 11]. The expression of STC-1 was computed relative to the expression of a reference gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using the comparative cycle threshold method (delta-delta-CT). Reactions were 15 ul in volume and contained 25 ng of total RNA with a 260/280 absorbance ratio of no less than 1.8. Each reaction was performed in quadruplicate. Reverse transcription was first carried out for 30 minutes at 48°C followed by an enzyme activation phase of 10 minutes at 95°C. The subsequent amplification reaction was run for 40 cycles alternating between 95°C and 60°C for 15 sec and 1 minute, respectively. All steps were performed on an ABI Prism 7900 HT sequence detector. Sequence Detection Software 2.0 (Applied Biosystems, Foster City, CA, USA) was used for analysis. Efficiencies above 90% were deemed acceptable. Amplified cDNAs (amplicons) were also resolved on 2% agarose gels for comparison of size.
The results of in situ ligand binding (ISLB), immunocytochemistry (ICC), and in situ hybridization (ISH) are shown in panels A through F of Figure 1. The ISLB staining revealed large numbers of STC-1 receptor-positive cells within adult mouse pancreatic islets (Figure 1(a)). Binding activity was evenly distributed throughout the cell cytoplasm, whereas cell nuclei were notable by their absence of staining (red arrow in Figure 1(b)). While the majority of islet cells were receptor positive, a small population of cells both within the islets and on the islet periphery were clearly receptor-negative. In contrast, ligand binding was generally weak over acinar cells comprising the exocrine pancreas.
As receptor-bearing islet cells had a distribution pattern similar to that of insulin-producing β cells (i.e., centrally located), correlative immunocytochemistry was carried out on adult mouse islets using antibodies to both STC-1 and insulin. The results showed that the two ligands exhibited a high degree of co-localization (Figure 2(c)), implying a close physical proximity between STC-1 and the structures associated with insulin synthesis and storage.
In contrast to the close physical association between STC-1 and insulin in adult mice, this was not the case in pancreatic tissue from embryonic mice (e17.5). Indeed, embryonic islet cells were notable for their lack of STC-1 immunoreactivity (Figure 1(d)), whereas the acinar cell population was instead highly immunoreactive, the exact opposite of the pattern seen in adults. Similarly, in contrast to adults, ISLB staining revealed that STC-1 receptors were equally present in both endocrine and exocrine cells of e17 embryos, albeit at low levels (Figure 1(e)).
ISH staining revealed the presence of STC-1 mRNA throughout the islets, and with a distribution pattern similar to that seen by ISLB and ICC (Figure 1(f)). However, the transcript-positive sites revealed by ISH appeared to be smaller than the islet cells revealed by both ISLB and ICC, suggesting that the transcript might in fact be nuclear as opposed to cytoplasmic. To explore this further, we compared the sizes of islet cell nuclei revealed by ISLB, ISH, and hematoxylin staining (Figures 2(a)–2(c)). The results clearly showed that all transcript-positive sites (Figure 2(c)) were similar in size to cell nuclei revealed either by ISLB (Figure 2(a)) or hematoxylin staining (Figure 2(b)). This suggested that the majority of islet cell STC-1 mRNA was confined to the nucleus and not to the cytoplasm. Lastly, the number of transcript-positive nuclei was counted by hand in individual islets and compared to those revealed in adjacent tissue sections by hematoxylin staining. When expressed as numbers of nuclei per arbitrary unit of islet area, there was no significant difference in their relatives densities ( by ISH versus by hematoxylin (mean ± SEM; ; , Student’s t-test). Thus, the majority of islet cell nuclei contained STC-1 mRNA, implying that the STC-1 gene was expressed by the majority of islet cells.
In order to confirm that the pancreatic islets expressed the STC-1 gene, rat islets were isolated using a well established protocol and isolated RNA was subjected to real time qPCR analysis. Rat kidney and liver RNA were also analyzed for the sake of comparison. In addition, the amplicons were subjected to agarose gel electrophoresis for estimations of size. The results showed that the rat islet STC-1 amplicon was the same size as that in rat kidney (Figure 3(a)). However, the gene was expressed at much lower levels in the islets than in either liver or kidney (50–150-fold lower). Controls entailing the omission of reverse transcriptase or substituting water for RNA generated no amplicons (results not shown).
The present study has shown that STC-1 and insulin co-localize to a high degree in adult mouse pancreatic β cells. As the majority of cellular insulin is confined to secretory vesicles, most of the STC-1 immunoreactivity would appear to reside therein with insulin. This was reinforced by the ISH findings which revealed that the STC-1 gene is expressed by most if not all islet cells. Unexpectedly, the majority of STC-1 transcript was observed to be confined to cell nuclei as opposed to the cytoplasm. This is in contrast to mouse ovary , mouse kidney , and fish ovary , where the transcript is found for the most part in the cytoplasm. As nuclear mRNA was observed in all mice that were examined, it could be argued that the islet transcript has a slower rate of transit from the nucleus as compared to other cell types. However, in the absence of additional data such a scenario can only be viewed as speculative. Clearly therefore, further work is needed to clarify both the validity and significance of the nuclear transcript.
The tissue pattern of STC-1 mRNA distribution has been characterized by four laboratories [8, 12–14], three of which have ruled out the pancreas as a site of STC-1 gene expression [12–14]. However, as islets comprise only a small fraction of the pancreas as a whole, it is highly unlikely that the northern blotting used in these earlier studies could have revealed the low levels of gene expression observed here by qPCR in isolated islets. Interestingly, stanniocalcin-2 (STC-2), which is the product of a second related gene, also appears to be found in pancreatic tissue [15–17], although in this instance the ligand is found exclusively in glucagon-producing α cells . Nonetheless, the cellular source of STC-2 gene expression still remains to be established.
What the stanniocalcins (STC-1 and STC-2) are doing in pancreatic islet cells is perhaps the most important question that now needs to be addressed. In this regard, it is worth noting that in some cell lines (N2a, HeLa) STC-2 localizes to the ER and Golgi and has proven to be an integral component of the unfolded-protein response; to the extent that attenuating STC-2 gene expression significantly increases cell death . It is conceivable that STC-2 serves a related function in pancreatic α cells. STC-1, on the other hand, is known to target subcellular organelles such as cholesterol lipid droplets, cell nuclei, and mitochondria . In pancreas, the STC-1 transcript, ligand, and receptor are all present in the β cell, which would appear to be indicative of an intracrine signalling pathway. But what it might be doing in β cells can only be speculated on. However, in the view of the fact that STC-1 promotes respiratory uncoupling in liver, muscle, and kidney cells through mitochondrial targeting  and given the critical role that respiratory uncoupling plays in insulin release , STC-1 could very well have regulatory effects on insulin secretion.
Finally, the production of STC-1 by β cells appears to be a postnatal phenomenon. When e17.5 embryonic mouse pancreas was examined by ICC, STC-1 immunoreactivity was observed exclusively in exocrine pancreatic acinar cells. In contrast the islet cells, which at this stage of development are known to be actively synthesizing insulin and glucagon , were devoid of STC-1 immunoreactivity. In addition, ISLB revealed comparatively low levels of STC-1 receptors in embryonic islet cells, in marked contrast to that in adults. It would appear therefore that β cell synthesis of and targeting by STC-1 only becomes important postnatally. The significance of this developmental phenomenon and, more importantly, the role of STC-1 in the adult pancreas are the critical questions that now need to be addressed.
Funding was provided by the Canadian Institutes of Health Research and the Kidney Foundation of Canada.
- M. E. Gerritsen and G. F. Wagner, “Stanniocalcin: no longer just a fish tale,” Vitamins & Hormones, vol. 70, pp. 105–135, 2005.
- J. P. Ellard, C. R. McCudden, C. Tanega et al., “The respiratory effects of stanniocalcin-1 (STC-1) on intact mitochondria and cells: STC-1 uncouples oxidative phosphorylation and its actions are modulated by nucleotide triphosphates,” Molecular and Cellular Endocrinology, vol. 264, no. 1-2, pp. 90–101, 2007.
- D. Zaidi, K. A. James, and G. F. Wagner, “Passive immunization of lactating mice with stanniocalcin-1 antiserum reduces mammary gland development, milk fat content, and postnatal pup growth,” American Journal of Physiology, vol. 291, no. 5, pp. E974–E981, 2006.
- C. R. McCudden, K. A. James, C. Hasilo, and G. F. Wagner, “Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism,” The Journal of Biological Chemistry, vol. 277, no. 47, pp. 45249–45258, 2002.
- S. E. Stasko and G. F. Wagner, “Possible roles for stanniocalcin during early skeletal patterning and joint formation in the mouse,” Journal of Endocrinology, vol. 171, no. 2, pp. 237–248, 2001.
- C. R. McCudden, W. H. Tam, and G. F. Wagner, “Ovarian stanniocalcin in trout is differentially glycosylated and preferentially expressed in early stage oocytes,” Biology of Reproduction, vol. 65, no. 3, pp. 763–770, 2001.
- K. A. James, M. Seitelbach, C. R. McCudden, and G. F. Wagner, “Evidence for stanniocalcin binding activity in mammalian blood and glomerular filtrate,” Kidney International, vol. 67, no. 2, pp. 477–482, 2005.
- R. Varghese, C. K. C. Wong, H. Deol, G. F. Wagner, and G. E. DiMattia, “Comparative analysis of mammalian stanniocalcin genes,” Endocrinology, vol. 139, no. 11, pp. 4714–4725, 1998.
- D. J. Hill, R. J. Sedran, S. L. Brenner, and T. J. McDonald, “IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans,” Journal of Endocrinology, vol. 153, no. 1, pp. 15–25, 1997.
- J. Turner, O. Sazonova, H. Wang, A. Pozzi, and G. F. Wagner, “Induction of the renal stanniocalcin-1 gene in rodents by water deprivation,” Molecular and Cellular Endocrinology, vol. 328, no. 1-2, pp. 8–15, 2010.
- J. Turner, F. L. Xiang, Q. Feng, and G. F. Wagner, “The renal stanniocalcin-1 gene is differentially regulated by hypertonicity and hypovolemia in the rat,” Molecular and Cellular Endocrinology, vol. 331, no. 1, pp. 150–157, 2011.
- A. C. M. Chang, J. Janosi, M. Hulsbeek et al., “A novel human cDNA highly homologous to the fish hormone stanniocalcin,” Molecular and Cellular Endocrinology, vol. 112, no. 2, pp. 241–247, 1995.
- E. E. Moore, R. E. Kuestner, D. C. Conklin et al., “Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells,” Hormone and Metabolic Research, vol. 31, no. 7, pp. 406–414, 1999.
- H. S. Olsen, M. A. Cepeda, Q. Q. Zhang, C. A. Rosen, B. L. Vozzolo, and G. F. Wagner, “Human stanniocalcin: a possible hormonal regulator of mineral metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 5, pp. 1792–1796, 1996.
- A. C. M. Chang and R. R. Reddel, “Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2,” Molecular and Cellular Endocrinology, vol. 141, no. 1-2, pp. 95–99, 1998.
- G. E. DiMattia, R. Varghese, and G. F. Wagner, “Molecular cloning and characterization of stanniocalcin-related protein,” Molecular and Cellular Endocrinology, vol. 146, no. 1-2, pp. 137–140, 1998.
- K. Ishibashi, K. Miyamoto, Y. Taketani et al., “Molecular cloning of a second human stanniocalcin homologue (STC2),” Biochemical and Biophysical Research Communications, vol. 250, no. 2, pp. 252–258, 1998.
- D. Ito, J. R. Walker, C. S. Thompson et al., “Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties,” Molecular and Cellular Biology, vol. 24, no. 21, pp. 9456–9469, 2004.
- E. Heart, R. F. Corkey, J. D. Wikstrom, O. S. Shirihai, and B. E. Corkey, “Glucose-dependent increase in mitochondrial membrane potential, but not cytoplasmic calcium, correlates with insulin secretion in single islet cells,” American Journal of Physiology, vol. 290, no. 1, pp. E143–E148, 2006.
- P.-L. Herrera, J. Huarte, F. Sanvito, P. Meda, L. Orci, and J. D. Vassalli, “Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene,” Development, vol. 113, no. 4, pp. 1257–1265, 1991.